Filing Flows › Castle Biosciences (CSTL) › Q1 2025
Castle Biosciences (CSTL) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 5, 2025
Castle Biosciences (CSTL) reported revenue of $88.0M for the first quarter 2025 (Q1 2025), +21% from a year earlier and +2% from the quarter before. Operating margin was -31.7%, net loss $25.8M (29.4% of revenue).
Castle Biosciences, Q1 2025: revenue $88.0M (+21% year over year), operating margin -31.7%, net loss $25.8M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $88.0M | +2% | +21% |
| Operating profit | −$27.9M | — | — |
| Net earnings | −$25.8M | — | — |
| Operating cash flow | −$6.0M | — | — |
What changed
Revenue was $88.0M in Q1 2025, up 21% year over year and up 2% from the previous quarter. Dermatologic was the largest line at 72% of revenue. Non-Dermatologic added $11.4M year over year (up 83%), 76% of the total change.
Operating costs exceeded revenue by $27.9M, an operating margin of -31.7%. Total costs grew 48% against revenue growth of 21%. The fastest-growing cost line was Other operating costs (+1161%). The quarter ended with a net loss of $25.8M, after a profit of $9.6M the previous quarter.
Operating cash flow was −$6.0M. Non-cash charges added back $29.8M of depreciation and amortization and $11.2M of share-based compensation. Working capital and other items used $21.1M. Capital expenditures of $4.7M exceeded it, leaving free cash flow of −$10.8M.
Questions
What was Castle Biosciences' revenue in the first quarter 2025?
Castle Biosciences (CSTL) reported revenue of $88.0M for the first quarter 2025 (Q1 2025), +21% from a year earlier and +2% from the quarter before.
Was Castle Biosciences profitable in the first quarter 2025?
Operating loss was $27.9M (-31.7% of revenue) and net loss $25.8M.
Source: Castle Biosciences 10-Q on SEC EDGAR.